Publications & Presentations

Hematologic Malignancies

Clinical

Non-clinical

  • Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells. Hu C, et al. ASH 2017
  • Telomerase Inhibition Impairs Self-Renewal of b-Catenin Activated Myeloproliferative Neoplasm Progenitors. Ma W, et al. ASH 2017
  • Integrated Molecular Analysis Identifies Replicative Stress as Sensitizer to Imetelstat Therapy in AML. Bruedigam C, et al. ASH 2017
  • Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia. Rusbuldt JJ, et al. AACR 2017
  • Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. Mosoyan G, et al. Leukemia 2017 (advance online publication)
  • The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts. Bruedigam C, et al. ASH 2016
  • Telomerase Inhibition with Imetelstat Eradicates β-catenin Activated BC CML Stem Cells. Ma W, et al. ASH 2016
  • Myelosuppression in Patients Treated With the Telomerase Inhibitor Imetelstat is Not Mediated Through Activation of Toll-Like Receptors. Baerlocher GM, et al. AACR 2016
  • Impact of Hypomethylating Agents on hTERT Expression and Synergistic Effect in Combination With Imetelstat, a Telomerase Inhibitor, in Acute Myeloid Leukemia Cell Lines. Rusbuldt J, et al. AACR 2016
  • Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Bruedigam C, et al. Cell Stem Cell 2014
  • Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Malignant Megakaryopoiesis in Myeloproliferative Neoplasms (MPN). Iancu-Rubin C, et al. ASH 2014
  • Effects of Imetelstat on CD34+ Cells of Patients with Myelofibrosis. Wang X, et al. ASH 2014
  • Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals. Brunold C, et al. ASH 2011

Other relevant publications and resources

  • Characterization of Disease, Treatment Patterns, and Outcomes of Patients With Myelofibrosis: Analysis of Two United States Commercial Claims Databases. Mehra M, et al. ASH 2016
  • Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Newberry et al, Blood 2017
  • Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Spiegel et al, Blood Advances 2017
  • Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Kuykendall et al, Ann Hematol 2018
  • DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Gangat N, et al. JCO 2011
  • How I treat myelofibrosis. Cervantes F. Blood 2014
  • Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Tefferi A, et al. Blood 2013
  • How we treat lower-risk myelodysplastic syndromes. Fenaux P and Adès L. Blood 2013

Solid Tumors

Clinical

  • A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Chiappori AA, et al. Ann Oncol. 2015
  • A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung cancer. Chiappori A, et al. AACR 2013
  • Improved progression-free survival (PFS) in patients with short tumor telomere length: Subgroup analysis from a randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced NSCLC. Chiappori A, et al. AACR 2013
  • Imetelstat Sodium (GRN163L), a Telomerase Inhibitor: Tolerability, Pharmacokinetics and Pharmacodynamic Activity Using an Intermittent Once Every Four Weeks Dosing Schedule in Patients With Advanced Solid Tumors. Ratain MJ, et al. EORTC-NCI-AACR 2010
  • Intermittent Dosing of Imetelstat Sodium, a Telomerase Inhibitor, Induces Drug Exposure Consistent With In Vivo Tumor Growth Inhibition. Ratain MJ, et al. AACR-NCI-EORTC 2009

Non-clinical

Review Articles